X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (7) 7
female (7) 7
humans (7) 7
male (7) 7
index medicus (6) 6
carcinoma, non-small-cell lung - drug therapy (5) 5
lung cancer (5) 5
lung neoplasms - drug therapy (5) 5
middle aged (5) 5
oncology (5) 5
chemotherapy (4) 4
hematology, oncology and palliative medicine (4) 4
lung cancer, non-small cell (4) 4
adult (3) 3
aged, 80 and over (3) 3
analysis (3) 3
cancer (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
care and treatment (3) 3
clinical trials (3) 3
lung neoplasms - genetics (3) 3
lung neoplasms - pathology (3) 3
medical colleges (3) 3
mutation (3) 3
respiratory agents (3) 3
acquired-resistance (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cancer therapies (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
cisplatin (2) 2
egfr mutations (2) 2
gefitinib (2) 2
gene expression (2) 2
immunotherapy (2) 2
neoplasm staging (2) 2
pharmaceutical industry (2) 2
pharmaceuticals (2) 2
product development (2) 2
protein (2) 2
recruitment (2) 2
respiratory system (2) 2
survival (2) 2
toxicity (2) 2
tyrosine (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
abi-007 (1) 1
abraxane (1) 1
abridged index medicus (1) 1
adenocarcinomas (1) 1
adjuvant treatment (1) 1
advanced nsclc (1) 1
af-001jp (1) 1
afatinib (1) 1
albumins - administration & dosage (1) 1
albumins - adverse effects (1) 1
amplification (1) 1
anaplastic lymphoma kinase (1) 1
anemia - chemically induced (1) 1
antibodies, monoclonal (1) 1
antigens (1) 1
antigens, neoplasm - genetics (1) 1
antigens, neoplasm - immunology (1) 1
antigens, neoplasm - metabolism (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - blood (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
asian continental ancestry group (1) 1
audio frequencies (1) 1
autopsy (1) 1
biomarkers (1) 1
biomarkers, tumor - metabolism (1) 1
brain neoplasms - secondary (1) 1
cancer patients (1) 1
cancer vaccine (1) 1
carbazoles - adverse effects (1) 1
carbazoles - blood (1) 1
carbazoles - therapeutic use (1) 1
carboplatin (1) 1
carboplatin - administration & dosage (1) 1
carboplatin - adverse effects (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - immunology (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - secondary (1) 1
carcinomas (1) 1
central nervous system (1) 1
ch5424802 (1) 1
chemotherapy, adjuvant (1) 1
chi-square distribution (1) 1
cisplatin - administration & dosage (1) 1
class-i antigens (1) 1
clinical-trials (1) 1
codes (1) 1
cut-off (1) 1
cytolytic t-lymphocytes (1) 1
data processing (1) 1
death (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 822 - 835
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2018, Volume 13, Issue 10, pp. 1496 - 1507
Data regarding the pre-treatment intertumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity... 
RNA sequencing | Biomarkers | Tumor heterogeneity | RET fusion | Autopsy | Immune-related markers | RET | READ ALIGNMENT | ADENOCARCINOMAS | ACQUIRED-RESISTANCE | EGFR MUTATIONS | OPEN-LABEL | KINASE INHIBITOR | GENOME | AMPLIFICATION | ONCOLOGY | RESPIRATORY SYSTEM | FUSIONS | Lung Neoplasms - genetics | Humans | Aged, 80 and over | Female | Male | Aged | Genetic Heterogeneity | Evolution, Molecular
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.